Sector News

Actelion CEO says Basilea purchase would make no sense: paper

January 18, 2016
Life sciences

(Reuters) – Swiss drug maker Actelion’s chief executive quashed speculation over its possible interest in purchasing Basilea Pharmaceutica.

“Basilea has developed interesting medications. But the company already has a partner,” Chief Executive Jean-Paul Clozel was quoted as saying in an interview published on Swiss paper Finanz und Wirtschaft’s website on Friday.

“Since we’re interested in active substances and not financial opportunities, it wouldn’t make sense for us to buy Basilea.”

(Reporting by Brenna Hughes Neghaiwi)

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend